Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
112 studies found for:    SCHIZOPHRENIA 1
Show Display Options
Rank Status Study
1 Unknown  Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients
Condition: SCHIZOPHRENIA 1 (Disorder)
Intervention: Drug: fluvoxamine
2 Unknown  A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations
Condition: Schizophrenia
3 Terminated Imaging Cannabinoid CB1 Receptors in Schizophrenia
Condition: Schizophrenia
4 Withdrawn Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
Conditions: Bipolar 1 Disorder;   Schizophrenia;   Mental Disorder;   Nervous System Diseases
Interventions: Drug: Aripiprazole;   Device: Ingestible Event Marker (IEM)
5 Completed Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
Conditions: Bipolar 1 Disorder;   Schizophrenia;   Mental Disorder;   Nervous System Disorders
6 Completed DAAOI-1 Treatment for Treatment-resistant Schizophrenia
Condition: Schizophrenia
Interventions: Drug: DAAOI-1;   Drug: placebo
7 Completed
Has Results
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.;   Drug: PP3M 263 mg eq.;   Drug: PP3M 350 mg eq.;   Drug: PP3M 525 mg eq.;   Drug: Placebo (20% Intralipid);   Drug: PP1M 50 mg eq.;   Drug: PP1M 75 mg eq.;   Drug: PP1M 100 mg eq.;   Drug: PP1M 150 mg eq.
8 Completed Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia
Conditions: Schizophrenia;   Chinese Han People
9 Completed Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia
Conditions: Schizophrenia;   Chinese Han People
10 Completed GlyT-1 Inhibitor Treatment for Refractory Schizophrenia
Conditions: Schizophrenia;   Treatment Refractory
Interventions: Drug: GlyT-1 inhibitor-1;   Drug: Placebo
11 Recruiting A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Condition: Schizophrenia
Intervention: Drug: Paliperidone palmitate 3 month formulation (PP3M)
12 Completed Serotonin 1A Agonists and Cognition in Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: adjunctive treatment with buspirone;   Drug: placebo
13 Unknown  Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype
Condition: Schizophrenia
Interventions: Drug: Lexapro;   Drug: Cymbalta;   Drug: Placebo
14 Completed Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole
Conditions: Schizophrenia;   Mental Disorder;   Nervous System Diseases
Intervention: Device: MIND1 System
15 Completed
Has Results
A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: Asenapine 3x5mg followed by 1x15mg;   Drug: Asenapine 1x15mg followed by 3x5mg
16 Completed Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.
Condition: Schizophrenia
Intervention: Drug: GSK1018921
17 Recruiting Translational Neuroscience Optimization of GlyT1 Inhibitor
Condition: Cognitive Impairments Associated With Schizophrenia
Interventions: Drug: PF-03463275;   Drug: Placebo
18 Enrolling by invitation Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
Conditions: Schizophrenia;   Psychotic Disorders
Interventions: Drug: Aripiprazole;   Drug: Risperidone
19 Completed Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Conditions: Schizophrenia;   Psychotic Disorders
Interventions: Drug: Aripiprazole;   Drug: Quetiapine;   Drug: Ziprasidone;   Behavioral: Cognitive battery
20 Completed A Phase 1 Safety Study in Adults With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: ALKS 3831

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.